InvestorsObserver
×
News Home

Should You Buy Intellia Therapeutics Inc (NTLA) Stock After it Is Higher By 20.80% in a Week?

Wednesday, February 28, 2024 01:34 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Intellia Therapeutics Inc (NTLA) Stock After it Is Higher By 20.80% in a Week?

Overall market sentiment has been high on Intellia Therapeutics Inc (NTLA) stock lately. NTLA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NTLA!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With NTLA Stock Today?

Intellia Therapeutics Inc (NTLA) stock is higher by 4.67% while the S&P 500 has fallen -0.05% as of 1:26 PM on Wednesday, Feb 28. NTLA is higher by $1.45 from the previous closing price of $31.02 on volume of 1,394,728 shares. Over the past year the S&P 500 is up 27.45% while NTLA has fallen -17.57%. NTLA lost -$5.42 per share in the over the last 12 months. To screen for more stocks like Intellia Therapeutics Inc click here.

More About Intellia Therapeutics Inc

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Click Here to get the full Stock Report for Intellia Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App